HH&L Acquisition Co. (HHLA)

NYSE: HHLA · IEX Real-Time Price · USD
0.00 (0.00%)
Jun 1, 2023, 12:00 AM EDT - Market closed
Market Cap 173.02M
Revenue (ttm) n/a
Net Income (ttm) 9.34M
Shares Out 16.58M
EPS (ttm) 0.19
PE Ratio 54.92
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 444
Open 10.43
Previous Close 10.44
Day's Range 10.43 - 10.44
52-Week Range 9.80 - 10.68
Beta -0.01
Analysts n/a
Price Target n/a
Earnings Date Mar 31, 2023

About HHLA

HH&L Acquisition Co. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on healthcare or healthcare-related companies in Asian markets. The company was incorporated in 2020 and is based in Central, Hong Kong. [Read more]

Industry Shell Companies
Sector Financials
IPO Date Feb 5, 2021
Country Hong Kong
Stock Exchange NYSE
Ticker Symbol HHLA
Full Company Profile

Financial Performance

Financial Statements


DiaCarta Receives Accreditation by the College of American Pathologists (CAP)

PLEASNTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received ac...

3 weeks ago - GlobeNewsWire

DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American As...

1 month ago - GlobeNewsWire

DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted E...

5 months ago - GlobeNewsWire

DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience

DiaCarta Starts to Receive Samples for Oncuria ® Bladder Cancer Test at its CLIA Lab

5 months ago - GlobeNewsWire

HH&L Acquisition Co. Announces Closing of Upsized $414 Million Initial Public Offering and Exercise of Underwriters' Over-Allotment Option in Full

HONG KONG, Feb. 9, 2021 /PRNewswire/ -- HH&L Acquisition Co. (NYSE: HHLA.U) (the "Company") today announced the closing of its initial public offering of 41,400,000 units, which includes 5,400,000 uni...

2 years ago - PRNewsWire